Evidence map›Paper›PMID 42291060›Full record

ArticleAmerican journal of preventive cardiology2026

Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial.

Rosalynn Gill, Meredith A Carpenter, Amy Holstein, Ariadne Reyes Garcia, Ayman Alkholder, Aanchal Gupta, Vatsala Singh, Arshed A Quyyumi, Neda Rasouli, Ian J Neeland and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rosalynn GillSomaLogic Operating Company, Standard BioTools, 2945 Wilderness Pl, Boulder, CO 80301, USA.
Meredith A CarpenterSomaLogic Operating Company, Standard BioTools, 2945 Wilderness Pl, Boulder, CO 80301, USA.
Amy HolsteinSomaLogic Operating Company, Standard BioTools, 2945 Wilderness Pl, Boulder, CO 80301, USA.
Ariadne Reyes GarciaSomaLogic Operating Company, Standard BioTools, 2945 Wilderness Pl, Boulder, CO 80301, USA.
Ayman AlkholderEmory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, 1364 Clifton Rd NE, Atlanta, GA 30322, USA.
Aanchal GuptaUniversity of Colorado Anschutz, Division of Endocrinology, Metabolism and Diabetes, 1635 Aurora Ct, 6th Floor, Aurora, CO 80045, USA.
Vatsala SinghUniversity of Colorado Anschutz, Division of Endocrinology, Metabolism and Diabetes, 1635 Aurora Ct, 6th Floor, Aurora, CO 80045, USA.
Arshed A QuyyumiEmory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, 1364 Clifton Rd NE, Atlanta, GA 30322, USA.
Neda RasouliUniversity of Colorado Anschutz, Division of Endocrinology, Metabolism and Diabetes, 1635 Aurora Ct, 6th Floor, Aurora, CO 80045, USA.
Ian J NeelandUniversity Hospitals Cleveland Medical Center, University Hospitals, Harrington Heart & Vascular Institute, Department of Internal Medicine, Case Western Reserve University, 11100 Euclid Ave l, Mailstop Lakeside 5038, Cleveland, OH 44106, USA.
Stephen A WilliamsSomaLogic Operating Company, Standard BioTools, 2945 Wilderness Pl, Boulder, CO 80301, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardioprotective (CP) therapies such as GLP-1 RA, SGLT2i, and PCSK9i medications remain underutilized in cardiovascular (CV) risk management. Individualized risk assessment using blood-based proteomic testing, such as Residual Cardiovascular Risk (RCVR) scores, may help guide treatment decisions. Objective: To evaluate whether access to RCVR scores improves risk-concordant prescribing of CP medications in clinical practice. Methods: In this multicenter, open label, behavioral randomized trial, adults with type 2 diabetes eligible for CP medications underwent SomaScan™ proteomic testing. Participants were randomized to an informed (RCVR results shared with patient and clinicians) or uninformed arm (results withheld until study end). CP prescribing rate and sensitivity-to-change of RCVR to CP initiation were assessed by trial arm. Chi-square trend in proportions, one-sided 2-sample tests for equality of proportions, and one-sided paired Wilcoxon signed-rank tests were used for statistical analysis. Results: Among 377 baseline participants analyzed (59 % informed; mean age 66 ± 10.3 years; 45 % female), CP prescribing was significantly higher in the informed versus uninformed arm (32.1 % vs 9.6 %; OR 5.45; 95 % CI: 2.31-12.89; Conclusions: Disclosure of proteomic RCVR scores was associated with higher rates of CP prescribing and short-term reductions in proteomic risk scores among CP medication users; proteomics-based risk assessment may support personalized CV prevention.

Indexed as

Cardioprotective therapyCardiovascular risk stratificationProteomicsResidual cardiovascular riskRisk-aligned prescribingSomaScanType 2 diabetes mellitus

Identifiers

PMID42291060
PMCPMC13261207

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.